High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Merck raises full-year guidance on robust KEYTRUDA and new product momentum, while navigating acquisition-related EPS impact and pipeline setbacks.
Gilead Sciences posts higher revenue as its market-leading HIV drug portfolio continues to drive growth.
Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index down 0.7% and th
Merck's (MRK) "HIV pipeline" is brewing in the background, as weekly treatment are interesting and s
Merck beat Q2 earnings and sales estimates as strong oncology and newer products lift results, prompting the company to raise and narrow its 2026 sales outlook.
Moderna’s vaccine candidate targets a species of ebolavirus behind a deadly outbreak in the Democratic Republic of the Congo.
By Michael Erman and Christy Santhosh Aug 4 (Reuters) - Merck reported higher-than-expected second-quarter sales on Tuesday and raised its full-year revenue forecast on the strength of its top-selling
Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Merck (NYSE:MRK) shares moved higher in pre-market trading after the pharmaceutical company reported second-quarter 2026 results that exceeded Wall Street expectations and raised its full-year revenue guidance. Although Merck reduced its adjusted earnings outlook to reflect acquisition-related charges, investors welcomed the stronger-than-expected quarterly performance and improved sales forecast.
The pharma giant now expects adjusted earnings of $2.66 to $2.76 per share, down from a prior range of $5.04 to $5.16
Merck (MRK) delivered earnings and revenue surprises of +50.00% and +1.69%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Investing.com -- Merck reported significantly better-than-expected earnings for the second quarter, while narrowing and raising its full-year revenue outlook.
Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q2 CY2026, with sales up 5.1% year on year to $16.61 billion. The company expects the full year’s revenue to be around $66.8 billion, close to analysts’ estimates. Its non-GAAP loss of $0.13 per share was 49.5% above analysts’ consensus estimates.
Stock futures pointed to a strong opening Tuesday, a day after the Dow Jones Industrial Average set a new closing record, as Palantir led tech shares higher and oil prices fell further.
The drugmaker posts a narrower-than-expected quarterly loss fueled by growth in its oncology segment.
Merck slashed its profit outlook for the year due to charges tied to its acquisition of cancer biotech company Terns Pharmaceuticals.
Merck's new injectable version of Keytruda walloped sales expectations Tuesday, packing a $200 million-plus punch vs. Wall Street's forecasts.
Today Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...
SCHD charges just 0.06% per year, but taxable investors who lived through the March reconstitution discovered a second bill arriving in a very different form. Here is what the expense ratio line was never designed to show you.
Agilent Technologies Inc. (NYSE:A) just extended its diagnostics franchise into one of oncology’s toughest corners. On July 23, the company said European regulators had certified its PD-L1 IHC 22C3 pharmDx test, Code SK006, as a companion diagnostic for epithelial ovarian, fallopian tube, and primary peritoneal carcinoma. That lets pathologists flag patients who might benefit from […]
Merck & Co., Inc. (NYSE:MRK) outlined its HIV treatment and prevention strategy at an investor event following the International AIDS Conference, highlighting Phase III results for a once-weekly oral HIV regimen and its plans for a monthly oral pre-exposure prophylaxis, or PrEP, candidate. Comp
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
